- Predictmedix AI Inc. (PMED) launches AI-driven mobile diabetes screening in India.
- The platform offers non-invasive, instant diabetic risk scoring through smartphones.
- Significant opportunity in India with over 100 million diabetics.
Predictmedix AI Inc. (CSE: PMED | OTC: PMEDF | FRA: 3QP), a leader in AI-driven health solutions, is venturing into the consumer market with a groundbreaking mobile diagnostic tool designed for rapid, non-invasive diabetes screening. India has been identified as the initial market for this innovative platform, which aims to leverage the widespread use of smartphones to provide instant diabetic risk assessments without the need for traditional medical infrastructure.
The initiative combines advanced facial and biometric analysis with seamless smartphone delivery, rendering the diabetes screening process accessible and affordable for underserved populations across India. Dr. Rahul Kushwah, COO of Predictmedix AI, highlighted the urgent need for this solution, noting the significant number of undiagnosed diabetics in India, which is home to over 100 million people living with diabetes.
The platform's smartphone-based delivery offers instant diabetic risk scoring, underpinned by Predictmedix's proven non-invasive AI screening technology. Designed with user-friendliness in mind, it supports multiple languages to ensure broad accessibility. Furthermore, the platform complies with India's Digital Personal Data Protection (DPDP) Act, ensuring secure handling of user data.
Predictmedix AI's strategic move into India comes as the country faces a growing diabetes epidemic, with projections suggesting that nearly one in three adults could be diabetic or prediabetic by 2045. The convergence of rising diabetes cases and the proliferation of smartphone use, now exceeding 1.1 billion users in India, presents a unique opportunity for this mobile-first, AI-powered health solution.
